- Home
- PDD vs AMGN Comparison
PDD vs AMGN Comparison
Compare PDD & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDD
- AMGN
- Stock Information
- Founded
- PDD 2015
- AMGN 1980
- Country
- PDD Ireland
- AMGN United States
- Employees
- PDD N/A
- AMGN N/A
- Industry
- PDD Business Services
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PDD Consumer Discretionary
- AMGN Health Care
- Exchange
- PDD Nasdaq
- AMGN Nasdaq
- Market Cap
- PDD 173.5B
- AMGN 156.3B
- IPO Year
- PDD 2018
- AMGN N/A
- Fundamental
- Price
- PDD $120.22
- AMGN $287.44
- Analyst Decision
- PDD Buy
- AMGN Hold
- Analyst Count
- PDD 11
- AMGN 18
- Target Price
- PDD $131.73
- AMGN $320.11
- AVG Volume (30 Days)
- PDD 9.1M
- AMGN 2.0M
- Earning Date
- PDD 08-25-2025
- AMGN 10-29-2025
- Dividend Yield
- PDD N/A
- AMGN 3.31%
- EPS Growth
- PDD N/A
- AMGN 110.88
- EPS
- PDD 9.23
- AMGN 12.23
- Revenue
- PDD $57,179,362,067.00
- AMGN $34,917,000,000.00
- Revenue This Year
- PDD $9.93
- AMGN $8.99
- Revenue Next Year
- PDD $15.62
- AMGN $1.79
- P/E Ratio
- PDD $13.03
- AMGN $23.52
- Revenue Growth
- PDD 19.91
- AMGN 12.88
- 52 Week Low
- PDD $87.11
- AMGN $253.30
- 52 Week High
- PDD $155.67
- AMGN $339.17
- Technical
- Relative Strength Index (RSI)
- PDD 54.99
- AMGN 42.02
- Support Level
- PDD $120.01
- AMGN $284.87
- Resistance Level
- PDD $133.33
- AMGN $290.25
- Average True Range (ATR)
- PDD 4.32
- AMGN 4.52
- MACD
- PDD -0.03
- AMGN -0.74
- Stochastic Oscillator
- PDD 35.80
- AMGN 18.02
About PDD PDD Holdings Inc.
PDD Holdings operates commerce businesses in over 80 countries globally. Its main operations are Pinduoduo, a social commerce platform in China, and Temu, a global e-commerce marketplace. PDD also has a community group purchase business in China. PDD has built a network of sourcing, logistics, and fulfillment capabilities that support its underlying businesses.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.